Cancer of the Rectum
9
1
1
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
22.2%
2 terminated out of 9 trials
66.7%
-19.8% vs benchmark
22%
2 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial.
Efficacy of Neoadjuvant Folfirinox Regimen in Patients With Resectable Locally Advanced Rectal Cancer
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps
PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
Immunoscore in Rectal Cancer
5FU/VL Vs LV5FU2 + CPT11 in Stage II-III Resected Rectal Cancer